Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T16:10:57.352Z.
Calculation as of: 2026-10-06T16:10:57.352Z.
Quote observation: 2026-10-06T16:10:11.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2a39ca6935a26d8aa5af55aa8ea7db8fcfa7d32011c972ec9cce8dd9481767f6
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
BridgeBio Oncology Therapeutics Inc.
Market Cap
$289.99M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$288.14M
Price/OCF Ratio
N/A
TTM Avg
4132.33
3Y Avg
4132.33
5Y Avg
4132.33
Market Cap
$285.37M
Price/OCF Ratio
N/A
TTM Avg
2.51
3Y Avg
2.51
5Y Avg
2.51
Market Cap
$294.51M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$283.44M
Price/OCF Ratio
N/A
TTM Avg
55.15
3Y Avg
55.15
5Y Avg
55.15
Market Cap
$279.05M
Price/OCF Ratio
N/A
TTM Avg
108.55
3Y Avg
108.55
5Y Avg
108.55
Market Cap
$277.05M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BridgeBio Oncology Therapeutics Inc. (BBOT) | $289.99M | N/A | N/A | N/A | N/A |
| Abeona Therapeutics Inc. (ABEO)vs › | $288.14M | N/A | 4132.33 | 4132.33 | 4132.33 |
| Standard BioTools Inc. (LAB)vs › | $287.22M | N/A | N/A | N/A | N/A |
| Indaptus Therapeutics, Inc. (INDP)vs › | $285.37M | N/A | 2.51 | 2.51 | 2.51 |
| Larimar Therapeutics, Inc. (LRMR)vs › | $294.51M | N/A | N/A | N/A | N/A |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $283.44M | N/A | 55.15 | 55.15 | 55.15 |
| Aurora Cannabis Inc. (ACB)vs › | $279.05M | N/A | 108.55 | 108.55 | 108.55 |
| Fate Therapeutics, Inc. (FATE)vs › | $277.46M | N/A | N/A | N/A | N/A |
| SAB Biotherapeutics, Inc. (SABS)vs › | $277.05M | N/A | N/A | N/A | N/A |
| Benitec Biopharma Inc. (BNTC)vs › | $300.93M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
